Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 10:05:25 06/03/2026 pm IST			5-day change	1st Jan Change
5.402 ^EUR	-1.13%		-8.13%	-0.88%

24/02	Centauri Therapeutics Limited announced that it has received £30 million in funding from a group of investors	CI
03/02	Evotec Shares Surge Following Berenberg Buy Recommendation	DP

Deutsche Bank Research Lowers Evotec Target Price to 6 Euros - Maintains 'Hold' Rating

Published on 07/22/2025 at 02:38 pm IST - Modified on 07/22/2025 at 04:36 pm IST

dpa-AFX - Translated by Marketscreener - See original

EVOTEC SE

-1.13%

FRANKFURT (dpa-AFX) - Deutsche Bank Research has reduced its target price for Evotec from 7 to 6 euros following the company's downward revision of its 2025 guidance, while maintaining its "Hold" recommendation. In a study released Tuesday, analyst Fynn Scherzler lowered his earnings expectations for the biotech firm accordingly. However, he noted that Evotec is making faster-than-expected progress with its cost-cutting measures./mis/gl

Original study publication: Date not specified in study / Time not specified in study / CET Initial distribution of the original study: 22.07.2025 / 07:57 / CET

-----------------------

dpa-AFX Broker - Trader News from dpa-AFX

-----------------------

Latest news about Evotec SE

24/02	Centauri Therapeutics Limited announced that it has received £30 million in funding from a group of investors	CI
03/02	Evotec Shares Surge Following Berenberg Buy Recommendation	DP
03/02	EVOTEC : Upgraded to Buy by Berenberg	ZD
03/02	Berenberg Initiates Evotec with 'Buy' Rating – Target Price Set at 10 Euros	DP
13/01	Evotec says Michael Kaufman holds 5.03% of total voting rights and instruments in Evotec	RE
08/01	Evotec Receives Gates Foundation Grant to Deploy AI in Optimizing Monoclonal Antibodies	MT
08/01	Evotec Remains in Demand on Tradegate – Funding Secured for Subsidiary	DP
07/01	Evotec Continues Upward Trend Following Amgen's Acquisition of Dark Blue	DP
07/01	EVOTEC : RBC reiterates its Buy rating	ZD
06/01	Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million	DJ
05/01	Amgen Inc. acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company and Evotec SE in a transaction valued at $840 million.	CI
02/01	Evotec SE Announces Executive Changes	CI
17/12	Evotec SE Equity Buyback announced on August 6, 2024, has expired.	CI
09/12	Sources: Novo Nordisk Group Holding reduces stake in Evotec	DP
09/12	Evotec secondary ABB priced at EUR 5.10 per share, bookrunner says	RE

Chart Evotec SE

Duration

Period

EVT: Dynamic Chart

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâ€™s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Employees

4,788

Sector

Biotechnology & Medical Research

More about the company